AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29685026 — intervention group
Group type: EXPERIMENTAL
Intervention: Biophysical therapy using a Med Select 729 device
Number of subjects: 150
Study 29685026 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (non-steroidal anti-inflammatory drug)
Number of subjects: 150
Study 29685026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 26699917 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 0
Study 26699917 — intervention group
Group type: COMPARATOR
Intervention: Supine positioning
Number of subjects: 0
Study 26699917 — intervention group
Group type: EXPERIMENTAL
Intervention: VAP (as a time-dependent covariate)
Number of subjects: 0
Study 25234648 — intervention group
Group type: EXPERIMENTAL
Intervention: Elosulfase alfa at 2.0 mg/kg administered weekly for 24 weeks
Number of subjects: 0
Study 25234648 — intervention group
Group type: EXPERIMENTAL
Intervention: Elosulfase alfa at 2.0 mg/kg administered every other week for 24 weeks
Number of subjects: 0
Study 25234648 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly dosing cohort
Number of subjects: 0
Study 25234648 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dosing cohorts
Number of subjects: 0
Study 23261008 — intervention group
Group type: EXPERIMENTAL
Intervention: PSYMEPHY (interdisciplinary treatment, 12 sessions)
Number of subjects: 153
Study 23261008 — intervention group
Group type: COMPARATOR
Intervention: Standard pharmacologic therapy (control group)
Number of subjects: 153
Study 20538493 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 0
Study 20538493 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 18690162 — intervention group
Group type: EXPERIMENTAL
Intervention: tesamorelin 2 mg
Number of subjects: 273
Study 18690162 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 273
Study 17006977 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic polypropylene mesh (n = 36)
Number of subjects: 74
Study 17006977 — intervention group
Group type: COMPARATOR
Intervention: No polypropylene mesh (n = 38)
Number of subjects: 74
Study 14530468 — intervention group
Group type: EXPERIMENTAL
Intervention: (99m)Tc‐MIBI SPECT
Number of subjects: 29
Study 10746426 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg once-weekly
Number of subjects: 1258
Study 10746426 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 35 mg twice-weekly
Number of subjects: 1258
Study 10746426 — intervention group
Group type: COMPARATOR
Intervention: Alendronate 10 mg daily
Number of subjects: 1258
Study 10746426 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 1258
Study 10746426 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly dosing group
Number of subjects: 1258
Study 8636828 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (1500 micrograms of beclomethasone via spacer for 30 days)
Number of subjects: 49
Study 8636828 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment without inhaled corticosteroids
Number of subjects: 49
Study 1609941 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 30
Study 1609941 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 30
Study 4054524 — intervention group
Group type: EXPERIMENTAL
Intervention: Polycose meal volume of 300 ml
Number of subjects: 21
Study 4054524 — intervention group
Group type: EXPERIMENTAL
Intervention: Polycose meal energy density of 0.7 kcal/ml
Number of subjects: 21
Study 4054524 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mean rate of caloric emptying
Number of subjects: 21
Study 4054524 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial 30 min period
Number of subjects: 21
Study 4054524 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased meal volume or energy density
Number of subjects: 21
Study 31895638 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfluorohexyloctane eye drops
Number of subjects: 48
Study 31895638 — intervention group
Group type: COMPARATOR
Intervention: Unpreserved 0.9% saline solution (Hydrabak®) eye drops
Number of subjects: 48
Study 31895638 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 48
Study 29976109 — intervention group
Group type: EXPERIMENTAL
Intervention: Theoretical narrative medicine education for 1 term (Group 2)
Number of subjects: 180
Study 29976109 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative medicine education integrating theory with practice for 2 terms (Group 3)
Number of subjects: 180
Study 29976109 — intervention group
Group type: COMPARATOR
Intervention: Regular medical education courses (Group 1)
Number of subjects: 180
Study 27515419 — intervention group
Group type: EXPERIMENTAL
Intervention: cilnidipine (N/L type CCB)
Number of subjects: 60
Study 27515419 — intervention group
Group type: COMPARATOR
Intervention: amlodipine (L type CCB)
Number of subjects: 60
Study 24573731 — intervention group
Group type: EXPERIMENTAL
Intervention: L-menthol (20 mL of 1.6% L-menthol)
Number of subjects: 226
Study 24573731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study 22541143 — intervention group
Group type: COMPARATOR
Intervention: Primary Closure (PC)
Number of subjects: 70
Study 22541143 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed Primary Closure (DPC)
Number of subjects: 70
Study 20213833 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg lorazepam
Number of subjects: 20
Study 20213833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 18478333 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Communications (FC) activities
Number of subjects: 40
Study 18478333 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth Anti‐tobacco Activities (YAT)
Number of subjects: 40
Study 18478333 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 40
Study 15829018 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast (leucotriene antagonist) for four weeks, along with doxycycline
Number of subjects: 17
Study 15829018 — intervention group
Group type: COMPARATOR
Intervention: Placebo for four weeks, along with doxycycline
Number of subjects: 17
Study 12005317 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (5 to 15 mg)
Number of subjects: 20
Study 12005317 — intervention group
Group type: COMPARATOR
Intervention: Control group (NF1 without ADHD)
Number of subjects: 20
Study 12005317 — intervention group
Group type: COMPARATOR
Intervention: Control group (ADHD without NF1)
Number of subjects: 20
Study 12005317 — intervention group
Group type: COMPARATOR
Intervention: Control group (normally developing children)
Number of subjects: 20
Study 11199824 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Nd:YAG laser treatment at cervical regions with black ink
Number of subjects: 54
Study 11199824 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Nd:YAG laser treatment at cervical regions without black ink
Number of subjects: 54
Study 11199824 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Nd:YAG laser treatment at apical regions with black ink
Number of subjects: 54
Study 11199824 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Nd:YAG laser treatment at apical regions without black ink
Number of subjects: 54
Study 8705220 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of norfloxacin twice daily for one week
Number of subjects: 491
Study 8705220 — intervention group
Group type: COMPARATOR
Intervention: 400 mg of norfloxacin twice daily for one day
Number of subjects: 491
Study 8705220 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of norfloxacin twice daily for one week (in patients with risk factors)
Number of subjects: 491
Study 8705220 — intervention group
Group type: COMPARATOR
Intervention: 400 mg of norfloxacin twice daily for one day (in patients with risk factors)
Number of subjects: 491
Study 1846868 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (GnRH-a) alone
Number of subjects: 8
Study 1846868 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CEE and MPA with GnRH-a
Number of subjects: 8
Study 1846868 — intervention group
Group type: COMPARATOR
Intervention: CEE alone
Number of subjects: 8
Study 1846868 — intervention group
Group type: COMPARATOR
Intervention: MPA alone
Number of subjects: 8
Study 1846868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6357043 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (180 mg)
Number of subjects: 20
Study 6357043 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (30 mg)
Number of subjects: 20
Study 6357043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30862556 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic restorative treatment (ART)
Number of subjects: 99
Study 30862556 — intervention group
Group type: COMPARATOR
Intervention: Conventional restorative technique (CT)
Number of subjects: 99
Study 29448259 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotating needles device (RND)
Number of subjects: 34
Study 27488212 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU + CBT4CBT
Number of subjects: 68
Study 27488212 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT4CBT + monitoring
Number of subjects: 68
Study 27488212 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 68
Study 27488212 — intervention group
Group type: EXPERIMENTAL
Intervention: All CBT4CBT conditions
Number of subjects: 68
Study 24696507 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐04494700 60 mg/day × 6 days, then 20 mg daily (high dose)
Number of subjects: 399
Study 24696507 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐04494700 15 mg/day × 6 days, then 5 mg daily (low dose)
Number of subjects: 399
Study 24696507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 399
Study 22530777 — intervention group
Group type: EXPERIMENTAL
Intervention: Replica running shoes
Number of subjects: 12
Study 22530777 — intervention group
Group type: COMPARATOR
Intervention: Original running shoes
Number of subjects: 12
Study 20203165 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐flux polyamide membrane
Number of subjects: 46
Study 20203165 — intervention group
Group type: COMPARATOR
Intervention: Low‐flux polyamide membrane
Number of subjects: 46
Study 17608154 — intervention group
Group type: EXPERIMENTAL
Intervention: MUPPP
Number of subjects: 30
Study 17608154 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 30
Study 17608154 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-OSAHS)
Number of subjects: 30
Study 17608154 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (10 patients)
Number of subjects: 30
Study 15297165 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐HPR (200 mg/day)
Number of subjects: 39
Study 15297165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 11270943 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast 20 mg twice daily
Number of subjects: 0
Study 11270943 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast 40 mg twice daily
Number of subjects: 0
Study 11270943 — intervention group
Group type: COMPARATOR
Intervention: Zafirlukast
Number of subjects: 0
Study 11270943 — intervention group
Group type: COMPARATOR
Intervention: Inhaled fluticasone propionate 88 microg or salmeterol 42 microg
Number of subjects: 0
Study 9840560 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration of 0.5% bupivacaine before incision (Treatment group A)
Number of subjects: 57
Study 9840560 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline placebo before skin incision and bupivacaine after laparoscopy (Treatment group B)
Number of subjects: 57
Study 9840560 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo before and after laparoscopy (Treatment group C)
Number of subjects: 57
Study 8206772 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotaped procedural modeling information
Number of subjects: 145
Study 8206772 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotaped procedural-sensory modeling information
Number of subjects: 145
Study 8206772 — intervention group
Group type: COMPARATOR
Intervention: Procedural-sensory information booklet
Number of subjects: 145
Study 8206772 — intervention group
Group type: EXPERIMENTAL
Intervention: All three preparatory informational treatments
Number of subjects: 145
Study 8206772 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported anxiety (SUDS)
Number of subjects: 145
Study 8206772 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiologic measures (heart rate and blood pressure)
Number of subjects: 145
Study 2648645 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (200 micrograms by inhalation)
Number of subjects: 7
Study 2648645 — intervention group
Group type: COMPARATOR
Intervention: Platelet activating factor
Number of subjects: 7
Study 30882244 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum DR7 (1×10^9 cfu/day) for 12 weeks
Number of subjects: 111
Study 28838366 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Number of subjects: 14
Study 28838366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 25223696 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% (w/w) fructose (F100)
Number of subjects: 12
Study 25223696 — intervention group
Group type: EXPERIMENTAL
Intervention: 90% fructose+10% glucose (F90G10)
Number of subjects: 12
Study 25223696 — intervention group
Group type: EXPERIMENTAL
Intervention: 55% fructose+45% glucose (F55G45)
Number of subjects: 12
Study 25223696 — intervention group
Group type: COMPARATOR
Intervention: 100% glucose (G100)
Number of subjects: 12
Study 25223696 — intervention group
Group type: EXPERIMENTAL
Intervention: F100 and F90G10
Number of subjects: 12
Study 25223696 — intervention group
Group type: EXPERIMENTAL
Intervention: F100
Number of subjects: 12
Study 23965191 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block (local anesthetic)
Number of subjects: 2
Study 23965191 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 2
Study 23965191 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 2
Study 21799444 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuminuria (normal range)
Number of subjects: 540
Study 21799444 — intervention group
Group type: COMPARATOR
Intervention: eGFR
Number of subjects: 540
Study 19451431 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX4 (oxaliplatin, fluorouracil, and leucovorin)
Number of subjects: 2246
Study 19451431 — intervention group
Group type: COMPARATOR
Intervention: LV5FU2 (fluorouracil and leucovorin)
Number of subjects: 2246
Study 16060912 — intervention group
Group type: COMPARATOR
Intervention: GnRHa alone (Group A)
Number of subjects: 26
Study 16060912 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa with GH (Group B)
Number of subjects: 26
Study 10599554 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone + fluoride (2.5 mg of tibolone + 26.4 mg of fluoride daily for 2 years)
Number of subjects: 94
Study 10599554 — intervention group
Group type: COMPARATOR
Intervention: Placebo + fluoride (placebo + 26.4 mg of fluoride daily for 2 years)
Number of subjects: 94
Study 8541006 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 6797
Study 2024543 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (2.5 to 40 mg daily, mean 18.3 mg)
Number of subjects: 253
Study 2024543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study 2024543 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 253
Study 6168856 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg digitoxin
Number of subjects: 8
Study 6168856 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg digitoxin
Number of subjects: 8
Study 6168856 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg digoxin
Number of subjects: 8
Study 6168856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31788233 — intervention group
Group type: EXPERIMENTAL
Intervention: ICT-CCS intervention
Number of subjects: 4100
Study 30295536 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment with a sling
Number of subjects: 146
Study 30295536 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixation with a pre‐contoured plate and locking screws
Number of subjects: 146
Study 26975533 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe energy deficit (ED; 3681±716 kcal/d energy deficit)
Number of subjects: 23
Study 26975533 — intervention group
Group type: COMPARATOR
Intervention: Energy balance (EB; 36±93 kcal/d energy deficit)
Number of subjects: 23
Study 24472398 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg OROS hydromorphone
Number of subjects: 23
Study 24472398 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg OROS hydromorphone
Number of subjects: 23
Study 24472398 — intervention group
Group type: EXPERIMENTAL
Intervention: 32 mg OROS hydromorphone
Number of subjects: 23
Study 24472398 — intervention group
Group type: EXPERIMENTAL
Intervention: 64 mg OROS hydromorphone
Number of subjects: 23
Study 24472398 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg naltrexone (concomitant with hydromorphone)
Number of subjects: 23
Study 22496918 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuously abstinent (biochemically confirmed abstinence at 6 months, 1 year, and 3 years post-quit attempt)
Number of subjects: 795
Study 22496918 — intervention group
Group type: COMPARATOR
Intervention: Smoked continuously (reported smoking at all three time points)
Number of subjects: 795
Study 22496918 — intervention group
Group type: COMPARATOR
Intervention: Intermittently abstinent (reported smoking at one of the three time points)
Number of subjects: 795
Study 20639832 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral amino acid (5%) supplementation
Number of subjects: 60
Study 20639832 — intervention group
Group type: COMPARATOR
Intervention: Usual nutritional management (10% intravenous dextrose and subsequent enteral feeding)
Number of subjects: 60
Study 17931979 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg loading dose then 75 mg daily)
Number of subjects: 392
Study 17931979 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg daily)
Number of subjects: 392
Study 17931979 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for clopidogrel)
Number of subjects: 392
Study 17931979 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for simvastatin)
Number of subjects: 392
Study 17931979 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 392
Study 17931979 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 392
Study 15821100 — intervention group
Group type: EXPERIMENTAL
Intervention: SFA diet (38% fat: 20% SFA, 12% MUFA, 6% PUFA)
Number of subjects: 59
Study 15821100 — intervention group
Group type: COMPARATOR
Intervention: CHO diet (<10% SFA, 12% MUFA, 6% PUFA)
Number of subjects: 59
Study 15821100 — intervention group
Group type: COMPARATOR
Intervention: Mediterranean diet (<10% SFA, 22% MUFA, 6% PUFA)
Number of subjects: 59
Study 11909567 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum lipoprotein(a) (≥20 mg/dl) and high low-density lipoprotein (LDL) cholesterol (≥3.63 mmol/L [≥140 mg/dl])
Number of subjects: 400
Study 11909567 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum lipoprotein(a) (≥20 mg/dl) and high low-density lipoprotein (LDL) cholesterol (≥3.63 mmol/L [≥140 mg/dl]) combined with type 2 diabetes mellitus
Number of subjects: 400
Study 9817951 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (part of a multidisciplinary treatment package)
Number of subjects: 22
Study 9817951 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cognitive behavioural therapy)
Number of subjects: 22
Study 9638201 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys with lipid risk factors for atherosclerosis
Number of subjects: 45
Study 9638201 — intervention group
Group type: COMPARATOR
Intervention: Boys without lipid risk factors for atherosclerosis (Control)
Number of subjects: 45
Study 9638201 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased serum cholesterol level
Number of subjects: 45
Study 9638201 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased serum HDL-cholesterol concentration
Number of subjects: 45
Study 2695151 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (5 mg/day for three months)
Number of subjects: 50
Study 2695151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 31285667 — intervention group
Group type: EXPERIMENTAL
Intervention: E-mail messages with problem-solving content
Number of subjects: 5449
Study 29100550 — intervention group
Group type: EXPERIMENTAL
Intervention: LPG stoves and fuel distribution
Number of subjects: 180
Study 29100550 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving LPG stoves and vouchers for free fuel
Number of subjects: 180
Study 25511685 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg twice daily
Number of subjects: 0
Study 25511685 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily
Number of subjects: 0
Study 24054380 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypropylene mesh (PM) implant
Number of subjects: 100
Study 24054380 — intervention group
Group type: COMPARATOR
Intervention: Traditional anterior vaginal wall colporraphy (Control)
Number of subjects: 100
Study 20646849 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (RT)
Number of subjects: 94
Study 20646849 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranially reduced clinical target volume (CTV) to the S2-S3 interspace
Number of subjects: 94
Study 20646849 — intervention group
Group type: COMPARATOR
Intervention: No primary nodal involvement and negative circumferential resection margin (CRM)
Number of subjects: 94
Study 20663491 — intervention group
Group type: EXPERIMENTAL
Intervention: Worry Exposure (WE)
Number of subjects: 113
Study 20663491 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio-Photic Stimulation (APS)
Number of subjects: 113
Study 20663491 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive Writing (EW)
Number of subjects: 113